Role of cellular iron and oxygen in the regulation of HIV-1 infection

Future Virology

Volumn 8, Issue 3, 2013, Pages 301-311

  Nekhai, Sergei ^a   Kumari, Namita ^a   Dhawan, Subhash ^b  

^a HOWARD UNIVERSITY   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

CDK2; CDK9; HIV 1; hypoxia; iron chelators; protein phosphatase 1; Tat

Indexed keywords

CICLOPIROX; DEFERIPRONE; IRON; OXYGEN; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPOXIA; IRON METABOLISM; IRON OVERLOAD; MACROPHAGE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 84874698903     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.6     Document Type: Review

References (119)

1. Lafeuillade A, Stevenson M. The search for a cure for persistent HIV reservoirs. AIDS Rev. 13(2), 63-66 (2011).
2. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert Jr. Iron status and the outcome of HIV infection: an overview. J. Clin. Virol. 20(3), 111-115 (2001).
3. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat. Rev. Microbiol. 6(7), 541-552 (2008).
4. Charles S, Ammosova T, Cardenas J et al. Regulation of HIV-1 transcription at 3% versus 21% oxygen concentration. J. Cell. Physiol. 221(2), 469-479 (2009).
5. Drakesmith H, Chen N, Ledermann H, Screaton G, Townsend A, Xu XN. HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis. Proc. Natl Acad. Sci. USA 102(31), 11017-11022 (2005).
6. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect. Agents Dis. 5(1), 36-46 (1996).
7. Rawat R, Humphrey J, Ntozini R, Mutasa K, Iliff P, Stoltzfus R. Elevated iron stores are associated with HIV disease severity and mortality among postpartum women in Zimbabwe. Public Health Nutr. 12(9), 1321-1329 (2008).
8. McDermid JM, Jaye A, Schim van der Loeff MF et al. Elevated iron status strongly predicts mortality in west African adults with HIV infection. J. Acquir. Immune Defic. Syndr. 46(4), 498-507 (2007).
9. McDermid JM, Van Der Loeff MF, Jaye A et al. Mortality in HIV infection is independently predicted by host iron status and SLC11a1 and hp genotypes, with new evidence of a gene-nutrient interaction. Am. J. Clin. Nutr. 90(1), 225-233 (2009).
10. Tsimberidou AM, Alvarado Y, Giles FJ. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev. Anticancer Ther. 2(4), 437-448 (2002).
11. Nekhai S, Jeang KT. Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol. 1(4), 417-426 (2006).
12. Debebe Z, Ammosova T, Breuer D et al. Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets -iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol. Pharmacol. 79(1), 185-196 (2011).
13. Debebe Z, Ammosova T, Jerebtsova M et al. Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology 367(2), 324-333 (2007).
14. Xu M, Kashanchi F, Foster A et al. Hepcidin induces HIV-1 transcription inhibited by ferroportin. Retrovirology 7, 104 (2010).
15. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res. 28(3), 663-668 (2000).
16. Chen L, Xiong S, She H, Lin SW, Wang J, Tsukamoto H. Iron causes interactions of TAK1, p21RAS, and phosphatidylinositol 3-kinase in caveolae to activate IkB kinase in hepatic macrophages. J. Biol. Chem. 282(8), 5582-5588 (2007).
17. Xiong S, She H, Takeuchi H et al. Signaling role of intracellular iron in NF-kB activation. J. Biol. Chem. 278(20), 17646-17654 (2003).
18. Xiong S, She H, Tsukamoto H. Signaling role of iron in NF-kappa B activation in hepatic macrophages. Comp. Hepatol. 3(Suppl. 1), S36 (2004).
19. Kim YS, Kang KR, Wolff EC, Bell JK, Mcphie P, Park MH. Deoxyhypusine hydroxylase is a Fe(II)-dependent, heat-repeat enzyme. Identification of amino acid residues critical for Fe(II) binding and catalysis. J. Biol. Chem. 281(19), 13217-13225 (2006).
20. Hoque M, Hanauske-Abel HM, Palumbo P et al. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 6, 90 (2009).
21. Barthelme D, Scheele U, Dinkelaker S et al. Structural organization of essential iron-sulfur clusters in the evolutionarily highly conserved ATP-binding cassette protein ABCE1. J. Biol. Chem. 282(19), 14598-14607 (2007).
22. Zimmerman C, Klein KC, Kiser PK et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 415(6867), 88-92 (2002).
23. Berkhout B, Silverman RH, Jeang KT. Tat transactivates the human immunodeficiency virus through a nascent RNA target. Cell 59(2), 273-282 (1989).
24. Wilhelm E, Doyle MC, Nzaramba I, Magdzinski A, Dumais N, Bell B. CTGC motifs within the HIV core promoter specify Tat-responsive pre-initiation complexes. Retrovirology 9, 62 (2012).
25. Nakamura M, Basavarajaiah P, Rousset E et al. Spt6 levels are modulated by PAAF1 and proteasome to regulate the HIV-1 LTR. Retrovirology 9, 13 (2012).
26. Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 414(6861), 317-322 (2001).
27. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 414(6861), 322-325 (2001).
28. He N, Jahchan NS, Hong E et al. A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. Mol. Cell 29(5), 588-599 (2008).
29. Krueger BJ, Jeronimo C, Roy BB et al. LARP7 is a stable component of the 7SK snRNP while P-TEFb, HAXIM1 and hnRNP A1 are reversibly associated. Nucleic Acids Res. 36(7), 2219-2229 (2008).
30. Markert A, Grimm M, Martinez J et al. The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and affects transcription of cellular and viral polymerase II genes. EMBO Rep. 9(6), 569-575 (2008).
31. Barboric M, Lenasi T, Chen H, Johansen EB, Guo S, Peterlin BM. 7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development. Proc. Natl Acad. Sci. USA 106(19), 7798-7803 (2009).
32. Jeronimo C, Forget D, Bouchard A et al. Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. Mol. Cell 27(2), 262-274 (2007).
33. Michels AA, Fraldi A, Li Q et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (Cdk9/cyclin T) inhibitor. EMBO J. 23(13), 2608-2619 (2004).
34. Sedore SC, Byers SA, Biglione S, Price JP, Maury WJ, Price DH. Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HAXIM1 to TAR. Nucleic Acids Res. 35(13), 4347-4358 (2007).
35. D'Orso I, Frankel AD. HIV-1 Tat: its dependence on host factors is crystal clear. Viruses 2(10), 2226-2234 (2010).
36. Sobhian B, Laguette N, Yatim A et al. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol. Cell 38(3), 439-451 (2010).
37. He N, Liu M, Hsu J et al. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol. Cell 38(3), 428-438 (2010).
38. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell 23(3), 297-305 (2006).
39. Czudnochowski N, Bosken CA, Geyer M. Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. Nat. Commun. 3, 842 (2012).
40. Kashanchi F, Agbottah ET, Pise-Masison CA et al. Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator. J. Virol. 74(2), 652-660 (2000).
41. Nekhai S, Shukla RR, Fernandez A, Kumar A, Lamb NJ. Cell cycle-dependent stimulation of the HIV-1 promoter by Tat-associated CAK activator. Virology 266(2), 246-256 (2000).
42. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV 1 promoter. J. Biol. Chem. 277(37), 33922-33929 (2002).
43. Nekhai S, Zhou M, Fernandez A et al. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem. J. 364(Pt 3), 649-657 (2002).
44. Agbottah E, De La Fuente C, Nekhai S et al. Antiviral activity of cyc202 in HIV-1-infected cells. J. Biol. Chem. 280(4), 3029-3042 (2005).
45. Pumfery A, De La Fuente C, Berro R, Nekhai S, Kashanchi F, Chao SH. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr. Pharm. Des. 12(16), 1949-1961 (2006).
46. Biglione S, Byers SA, Price JP et al. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, Seliciclib and Flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4, 47 (2007).
47. Galons H, Oumata N, Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin. Ther. Pat. 20(3), 377-404 (2010).
48. Carpio L, Klase Z, Coley W et al. MicroRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection. J. RNAi Gene Silencing 6(1), 386-400 (2010).
49. Chen R, Yang Z, Zhou Q. Phosphorylated positive transcription elongation factor b (P-TEFb) is tagged for inhibition through association with 7SK snRNA. J. Biol. Chem. 279(6), 4153-4160 (2004).
50. Li Q, Price JP, Byers SA, Cheng D, Peng J, Price DH. Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing CDK9 phosphorylated at threonine 186. J. Biol. Chem. 280(31), 28819-28826 (2005).
51. Chen R, Liu M, Li H et al. PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev. 22(10), 1356-1368 (2008).
52. Zhou M, Lu H, Park H, Wilson-Chiru J, Linton R, Brady JN. Tax interacts with P-TEFb in a novel manner to stimulate human T-lymphotropic virus type 1 transcription. J. Virol. 80(10), 4781-4791 (2006).
53. Ammosova T, Obukhov Y, Kotelkin A et al. Protein phosphatase-1 activates CDK9 by dephosphorylating ser175. PLOS One 6(4), e18985 (2011).
54. Ammosova T, Yedavalli VR, Niu X et al. Expression of a protein phosphatase 1 inhibitor, cdNIPP1, increases CDK9 threonine 186 phosphorylation and inhibits HIV-1 transcription. J. Biol. Chem. 286(5), 3798-3804 (2011).
55. Ammosova T, Platonov M, Yedavalli VR et al. Small molecules targeted to a non-catalytic 'RVxF' binding site of protein phosphatase-1 inhibit HIV-1. PLoS One 7(6), e39481 (2012).
56. Breuer D, Kotelkin A, Ammosova T et al. CDK2 regulates HIV-1 transcription by phosphorylation of CDK9 on serine 90. Retrovirology 9(1), 94 (2012).
57. Traore HN, Meyer D. The effect of iron overload on in vitro HIV-1 infection. J. Clin. Virol. 31(Suppl. 1), S92-S98 (2004).
58. Georgiou NA, Van Der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, Van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J. Infect. Dis. 181(2), 484-490 (2000).
59. Pahl PM, Reese SM, Horwitz LD. A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells. J. Exp. Ther. Oncol. 6(3), 193-200 (2007).
60. Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 98(3), 842-850 (2001).
61. Lucas JJ, Szepesi A, Domenico J et al. Effects of iron-depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the p33CDK2 kinase. Blood 86(6), 2268-2280 (1995).
62. Pahl PM, Yan XD, Hodges YK, Rosenthal EA, Horwitz MA, Horwitz LD. An exochelin of mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J. Biol. Chem. 275(23), 17821-17826 (2000).
63. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13, 261-291 (1997).
64. Coulonval K, Bockstaele L, Paternot S, Roger PP. Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis. J. Biol. Chem. 278(52), 52052-52060 (2003).
65. Richardson DR. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr. Med. Chem. 12(23), 2711-2729 (2005).
66. Wang G, Miskimins R, Miskimins WK. Regulation of p27(kip1) by intracellular iron levels. Biometals 17(1), 15-24 (2004).
67. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci. STKE 2007(407), cm8 (2007).
68. Guendel I, Carpio L, Easley R et al. 9-aminoacridine inhibition of HIV-1 Tat dependent transcription. Virol. J. 6, 114 (2009).
69. Wu W, Kehn-Hall K, Pedati C et al. Drug 9aa reactivates p21/WAF1 and inhibits HIV-1 progeny formation. Virol. J. 5, 41 (2008).
70. Ferreira A, Marguti I, Bechmann I et al. Sickle hemoglobin confers tolerance to plasmodium infection. Cell 145(3), 398-409 (2011).
71. Ammosova T, Berro R, Jerebtsova M et al. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3, 78 (2006).
72. Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu. Rev. Microbiol. 62, 425-443 (2008).
73. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc. Natl Acad. Sci. USA 102(5), 1324-1328 (2005).
74. Beaumont C. Multiple regulatory mechanisms act in concert to control ferroportin expression and heme iron recycling by macrophages. Haematologica 95(8), 1233-1236 (2010).
75. Williams TN, Mwangi TW, Wambua S et al. Sickle cell trait and the risk of plasmodium falciparum malaria and other childhood diseases. J. Infect. Dis. 192(1), 178-186 (2005).
76. Aidoo M, Terlouw DJ, Kolczak MS et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 359(9314), 1311-1312 (2002).
77. Devadas K, Dhawan S. Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. J. Immunol. 176(7), 4252-4257 (2006).
78. Devadas K, Hewlett IK, Dhawan S. Lipopolysaccharide suppresses HIV-1 replication in human monocytes by protein kinase c-dependent heme oxygenase-1 induction. J. Leukoc. Biol. 87(5), 915-924 (2010).
79. Finn AV, Nakano M, Polavarapu R et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J. Am. Coll. Cardiol. 59(2), 166-177 (2012).
80. Donovan A, Lima CA, Pinkus JL et al. The iron exporter ferroportin/slc40a1 is essential for iron homeostasis. Cell Metab. 1(3), 191-200 (2005).
81. Donovan A, Brownlie A, Zhou Y et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403(6771), 776-781 (2000).
82. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 275(26), 19906-19912 (2000).
83. Mckie AT, Marciani P, Rolfs A et al. A novel duodenal iron-regulated transporter, ireg1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 5(2), 299-309 (2000).
84. Ganz T. Molecular control of iron transport. J. Am. Soc. Nephrol. 18(2), 394-400 (2007).
85. Drakesmith H, Schimanski LM, Ormerod E et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 106(3), 1092-1097 (2005).
86. Schimanski LM, Drakesmith H, Merryweather-Clarke AT et al. In vitro functional analysis of human ferroportin (Fpn) and hemochromatosis-associated Fpn mutations. Blood 105(10), 4096-4102 (2005).
87. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl Acad. Sci. USA 98(15), 8780-8785 (2001).
88. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin. Hematol. 46(4), 387-393 (2009).
89. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol. 214(2), 231-241 (2008).
90. Ivanovic Z. Hypoxia or in situ normoxia: the stem cell paradigm. J. Cell. Physiol. 219(2), 271-275 (2009).
91. Meyron-Holtz EG, Ghosh MC, Rouault TA. Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 306(5704), 2087-2090 (2004).
92. Jiang JH, Wang N, Li A et al. Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. J. Clin. Virol. 37(2), 98-103 (2006).
93. Davis DA, Rinderknecht AS, Zoeteweij JP et al. Hypoxia induces lytic replication of kaposi sarcoma-associated herpesvirus. Blood 97(10), 3244-3250 (2001).
94. Servais C, Caillet-Fauquet P, Draps ML, Velu T, De Launoit Y, Brandenburger A. Hypoxic-response elements in the oncolytic parvovirus minute virus of mice do not allow for increased vector production at low oxygen concentration. J. Gen. Virol. 87(Pt 5), 1197-1201 (2006).
95. Shen BH, Bauzon M, Hermiston TW. The effect of hypoxia on the uptake, replication and lytic potential of group b adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther. 13(12), 986-990 (2006).
96. Puppo M, Bosco MC, Federico M, Pastorino S, Varesio L. Hypoxia inhibits moloney murine leukemia virus expression in activated macrophages. J. Leukoc. Biol. 81(2), 528-538 (2007).
97. Atkuri KR, Herzenberg LA, Niemi AK, Cowan T. Importance of culturing primary lymphocytes at physiological oxygen levels. Proc. Natl Acad. Sci. USA 104(11), 4547-4552 (2007).
98. Sahaf B, Atkuri K, Heydari K et al. Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease. Proc. Natl Acad. Sci. USA 105(13), 5111-5116 (2008).
99. Sargent PJ, Farnaud S, Evans RW. Structure/ function overview of proteins involved in iron storage and transport. Curr. Med. Chem. 12(23), 2683-2693 (2005).
100. Nekhai S, Bhat UG, Ammosova T et al. A novel anticancer agent ARC antagonizes HIV-1 and HCV. Oncogene 26(26), 3899-3903 (2007).
101. Nekhai S, Jerebtsova M, Jackson A, Southerland W. Regulation of HIV-1 transcription by protein phosphatase 1. Curr. HIV Res. 5(1), 3-9 (2007).
102. Taylor CT, Furuta GT, Synnestvedt K, Colgan SP. Phosphorylation-dependent targeting of camp response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc. Natl Acad. Sci. USA 97(22), 12091-12096 (2000).
103. Comerford KM, Leonard MO, Cummins EP et al. Regulation of protein phosphatase 1gamma activity in hypoxia through increased interaction with NIPP1: implications for cellular metabolism. J. Cell. Physiol. 209(1), 211-218 (2006).
104. Horree N, Gort EH, Van Der Groep P, Heintz AP, Vooijs M, Van Diest PJ. Hypoxia-inducible factor 1 alpha is essential for hypoxic p27 induction in endometrioid endometrial carcinoma. J. Pathol. 214(1), 38-45 (2008).
105. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States:national and state estimates national and state estimates. Am. J. Hematol. 85(1), 77-78.
106. Niu X, Nouraie M, Campbell A et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One 4(11), e7956 (2009).
107. Castro O, Saxinger C, Barnes S, Alexander S, Flagg R, Frederick W. Prevalence of antibodies to human immunodeficiency virus and to human T cell leukemia virus type I in transfused sickle cell disease patients. J. Infect. Dis. 162(3), 743-745 (1990).
108. Bagasra O, Steiner RM, Ballas SK et al. Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia. Am. J. Hematol. 59(3), 199-207 (1998).
109. Batina Agasa S, Dupont E, Kayembe T et al. Multiple transfusions for sickle cell disease in the democratic republic of congo: the importance of the hepatitis C virus. Transfus. Clin. Biol. 17(4), 254-259.
110. Batina A, Kabemba S, Malengela R. Infectious markers among blood donors in Democratic Republic of Congo (DRC). Rev. Med. Brux. 28(3), 145-149 (2007).
111. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sex. Transm. Infect. 88(7) 528-533 (2012).
112. Kroot JJ, Laarakkers CM, Kemna EH, Biemond BJ, Swinkels DW. Regulation of serum hepcidin levels in sickle cell disease. Haematologica 94(6), 885-887 (2009).
113. Jison ML, Munson PJ, Barb JJ et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood 104(1), 270-280 (2004).
114. O'Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb. Perspect. Med. 2(12), a007351 (2012).
115. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 338(6108), 768-772 (2012).
116. Harries AD, Hargreaves NJ, Kemp J et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 357(9267), 1519-1523 (2001).
117. Parikh N, Nonnemacher MR, Pirrone V, Block T, Mehta A, Wigdahl B. Substance abuse, HIV-1 and hepatitis. Curr. HIV Res. 10(7), 557-571 (2012).
118. Murray MJ, Murray AB, Murray MB, Murray CJ. The adverse effect of iron repletion on the course of certain infections. BMJ 2(6145), 1113-1115 (1978).
119. McDermid JM, Prentice AM. Iron and infection: effects of host iron status and the iron-regulatory genes Haptoglobin and NR AMP1 (SLC11a1) on host-pathogen interactions in tuberculosis and HIV. Clin. Sci. (Lond.) 110(5), 503-524 (2006).